Project description:Here is the genome sequence of Haloparvum sedimenti DYS4, the type species of the genus Haloparvum, isolated from a salt mine. The DNA G+C content of this genome was 68.27 mol%. The scaffold N50 was 96,635 bp. The completely sequenced and annotated genome is 3,243,052 bp and contains 3,313 genes.

| S-EPMC5721132 | biostudies-literature

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

Halomonas sedimenti strain:QX-2

Project description:Halomonas sedimenti strain:QX-2 Genome sequencing

| PRJNA638729 | ENA